Table 2.
Study characteristics regarding anti-phospholipid autoantibodies.
| Studies | Type of Study | Type of Auto-Antibodies | Study Group | Control Group | Clinical Pregnancy Rate | Live Birth/Ongoing Pregnancy Rate | Miscarriage Rate | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Study Group | Control Group | Study Group | Control Group | Study Group | Control Group | |||||
| Di Nisio et al., 2018 [43] | Prospective | Lupus anticoagulant, Anti-cardiolipin antibodies, Anti- β2-glycoprotein antibodies | 57 aPL (+) women | 598 aPL (−) women | 31.58% | 29.26% | 12.28% | 20.23% | 61.11% | 30.86% |
| Hong et al., 2018 [44] | Prospective | Lupus anticoagulant, Anti-cardiolipin antibodies, anti-β2-glycoprotein 1 antibody | 12 aPL (+) women | 181 aPL (−) women | 66.67% | 45.86% | 58.33% | 37.02% | 12.50% | 19.28% |
| Andreeva et al., 2017 [45] | Case Report | IgA-anti-β2GPI | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Chen et al., 2017 a [11] | Prospective | aCL-IgG, aCL-IgM, aβ2GPI-IgG, aβ2GPI-IgM | 193 aCL-IgG (+) women, 202 aCL-IgM (+) women, 22 aβ2GPI-IgG (+) women, 246 aβ2GPI-IgM (+) women | 844 aPL (−) women | 58.0% 63.4% 36.4% 55.7% |
61.02% | 48.18% 53.96% 31.81% 50.81% |
55.92% | 17.00% 14.8% 12.50% 8.80% |
8.35% |
| Orquevaux et al., 2017 b [46] | Retrospective | Lupus anticoagulant, Anti-cardiolipin antibodies, anti-β2-glycoprotein 1 antibody | 12 SLE + aPL(+)/APS women 10 APS women |
15 SLE + aPL (−) women | 25% | 32.43% | n/a | n/a | n/a | n/a |
| Paulmyer-Lacroix et al., 2014 [47] | Retrospective | Lupus anticoagulant, Anti-cardiolipin antibodies, IgA-anti-β2GPI | 8 aPL (+) women | 32 aPL (−) women | 50.00% | 53.13% | 0.00% | 18.75% | 100.00% | 64.71% |
| Da Costa et al., 2012 [48] | Retrospective | Lupus anticoagulant, Anti-cardiolipin antibodies | 34 aPL (+) women | 205 aPL (−) women | n/a | n/a | n/a | n/a | n/a | n/a |
| Ragab et al.,2012 [49] | Case Series | Lupus anticoagulant, Anti-cardiolipin antibodies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ulcova-Gallova, 2012 [50] | Case Series | Anti-cardiolipin antibodies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ying et al., 2012 [51] | Retrospective | Anti-cardiolipin antibodies | 60 ACA (+) women | 518 ACA (−) women | 26.67% | 44.98% | n/a | n/a | 31.25% | 15.88% |
| Zhong et al., 2011 [52] | Retrospective | Anti-cardiolipin antibodies | 80 ACA (+) women | 788 ACA (−) women | 31.25% | 48.60% | n/a | n/a | 32.00% | 19.32% |
| Lee et al., 2007 [53] | Prospective | Anti-cardiolipin antibody, lupus anticoagulant | 39 aPL (+) women | 142 aPL (−) women | 20.51% | 17.61% | 7.69% | 14.08% | 62.50% | 20.00% |
| Sanmarco et al., 2007 [54] | Prospective | Lupus anticoagulant, Anti-cardiolipin antibodies, anti-β2-glycoprotein 1 antibody | 40 aPL (+) women | 61 aPL (−) women | 27.50% | 19.67% | 22.50% | 13.11% | 18.18% | 33.33% |
| Buckingham et al., 2006 [55] | Prospective | Anti-cardiolipin antibodies, anti-β2-glycoprotein 1 antibody, phosphatidylserine | 19 aPL (+) women | 80 aPL (−) women | 31.58% | 36.25% | 15.79% | 23.75% | n/a | n/a |
| Matsubayashi et al., 2006 b [56] | Prospective | Anti-cardiolipin antibodies, anti-β2-glycoprotein 1 antibody, | 17 aPL (+) women | 27 aPL (−) women | 29.41% | 33.33% | n/a | n/a | n/a | n/a |
a: Chen et al., 2017, presents patients positive for more than one auto-antiboy, thus cumulative results cannot be provided; b: The data regarding the Matsubayashi et al., 2006 study were obtained from a letter to the editor by Matsubayashi and colleagues ([57]) for Buckingham et al., 2006 study.